We invest in highly innovative, scalable life science companies that have recently reached, or are close to, the commercial stage, with strong long-term potential.
The combination of our long-term capital and sector expertise position us as an investor of choice for growth companies in the life science sector.
We are an engaged investor in, and a partner to life science companies at the leading edge of innovation.
We invest in companies harnessing the transformative power of biology and technology. In particular, we focus on investments in clinical diagnostics, industrial biotechnology, biologics supply chain, and healthcare IT.
We leverage our deep scientific knowledge, operational expertise and global network for the benefit of our portfolio companies.
We manage evergreen capital, which allows us to have a longer-term horizon and be a true partner dedicated to enabling our portfolio companies to fulfil their potential.

€690m
Assets under Management by the end of 2024
11
Portfolio companies across the US and Europe
Search
Meet our team
News
12/7/2023
Novo Holdings joins USD 40.8 million Series C extension round for Doctor Anywhere, a tech-led healthcare provider based in Singapore

News
07/21/2025
MedGenome raises Series E funding, co-led by Maj Invest and Novo Holdings, to expand access to its genomics offerings in India

News
10/1/2025
Novo Holdings Announces Acquisition of Elektrofi by Halozyme
News
05/28/2019
Novo Holdings invests in leading gene and cell therapy group Oxford Biomedica